Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Co-administration of the Campylobacter jejuni N-glycan based vaccine with probiotics improves vaccine performance in broiler chickens.

Posted by on in 2017
  • Font size: Larger Smaller
  • Hits: 300
  • Print

Nothaft H1Perez-Muñoz ME2Gouveia GJ3,4Duar RM2Wanford JJ5Lango-Scholey L5Panagos CG4Srithayakumar V2,6Plastow GS2,6Coros C7Bayliss CD5Edison AS3,4Walter J8,2Szymanski CM9,4,10Appl Environ Microbiol. 2017 Sep 22. pii: AEM.01523-17. doi: 10.1128/AEM.01523-17. [Epub ahead of print]

Department of Biological Sciences, University of Alberta, Edmonton, Canada.
Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, Canada.
Departments of Genetics and Biochemistry and Molecular Biology, University of Georgia, Athens, USA.
Complex Carbohydrate Research Center, University of Georgia, Athens, USA.
Department of Genetics and Genome Biology, University of Leicester, Leicester, UK.
Livestock Gentec, Edmonton, Canada.
Delta Genomics, Edmonton, Canada.
Department of Biological Sciences, University of Alberta, Edmonton, Canada.
Department of Biological Sciences, University of Alberta, Edmonton, Canada.
Department of Microbiology, University of Georgia, Athens, USA.


Source attribution studies report that consumption of contaminated poultry is the primary source for acquiring human campylobacteriosis. Oral administration of an engineered Escherichia coli strain expressing the Campylobacter jejuni N-glycan reduces bacterial colonization in specific-pathogen-free leghorn chickens, but only a fraction of birds respond to vaccination. Optimizing the vaccine for commercial broiler chickens has great potential to prevent pathogen entry into the food chain. Here, we tested the same vaccination approach in broilers and observed similar efficacy in pathogen load reduction, stimulation of host IgY response, lack of C. jejuni resistance development, uniformity in microbial gut composition, and bimodal response to treatment. Gut microbiota analysis of leghorn and broiler vaccine responders identified one member of the Clostridiales XIVa cluster, Anaerosporobacter mobilis, significantly more abundant in responder birds. In broilers, co-administration of the live vaccine with A. mobilis or Lactobacillus reuteri, a commonly used probiotic, resulted in increased vaccine efficacy, antibody response, and weight gain. To investigate whether the responder/non-responder effect was due to selection of a C. jejuni 'super colonizer mutant' with altered phase-variable genes, we analysed all polyG-containing loci of the input strain compared to non-responder colony isolates and found no evidence of phase state selection. However, untargeted NMR-based metabolomics identified a potential biomarker negatively correlated with C. jejuni colonization levels possibly linked to the increased microbial diversity in this subgroup. The comprehensive methods used to examine the vaccine response bimodality provide several opportunities to improve the C. jejuni vaccine and the efficacy of any vaccination strategy.ImportanceCampylobacter jejuni is a common cause of human diarrheal disease worldwide and listed by the World Health Organization as a high priority pathogen. C. jejuni infection is typically through the ingestion of contaminated chicken meat, so many efforts are targeted to reduce C. jejuni levels at the source. We previously developed a vaccine that reduces C. jejunilevels in egg-laying chickens. In this study, we improved vaccine performance in meat birds by supplementing with probiotics. In addition, we demonstrated that C. jejuni colonization levels in chickens are negatively correlated with Clostridial abundance, another group of common gut microbes. We describe new methods for vaccine optimization that will assist in improving the C. jejuni vaccine and other vaccines under development.

 [Available on 2018-05-16]
Last modified on